However, the synergistic effects of SFI and gefitinib on gefitinib resistant NSCLC cells, which may become a promising strategy to overcome EGFR-TKIs resistance, and underlying mechanisms are poorly understood. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.